Core signaling pathways and new therapeutic targets in pancreatic cancer

Chinese Medical Journal

Volumn 123, Issue 9, 2010, Pages 1210-1215

  You, Lei ^a   Chen, Ge ^a   Zhao, Yu Pei ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Pancreatic cancer; Signaling pathway; Therapeutic target

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; API 12009; CYCLOPAMINE; CYTOKINE; GAMMA SECRETASE INHIBITOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR 7; INTERLEUKIN 2; K RAS PROTEIN; NOTCH RECEPTOR; PEPTIDE VACCINE; SMALL INTERFERING RNA; SONIC HEDGEHOG PROTEIN; TRANSFORMING GROWTH FACTOR; UNCLASSIFIED DRUG; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER RESISTANCE; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CLINICAL TRIAL; COLORECTAL CARCINOMA; DRUG TARGETING; GENE MUTATION; HUMAN; MELANOMA; MUTATIONAL ANALYSIS; NONHUMAN; PANCREAS CANCER; PATHOPHYSIOLOGY; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

HUMANS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 77952400159     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.09.020     Document Type: Review

References (70)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Gress TM, Wallrapp C, Frohme M, Müller-Pillasch F, Lacher U, Friess H, et al. Identification of genes with specific expression in pancreatic cancer by cDNA representational difference analysis. Genes Chromosomes Cancer 1997; 19: 97-103.
3. Hustinx SR, Cao D, Maitra A, Sato N, Martin ST, Sudhir D, et al. Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression. Cancer Biol Ther 2004; 3: 1254-1261.
4. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, Adsay NV, Shen-Ong GL, Berg K, et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 2003; 63: 8614-8622.
5. Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, van Heek NT, Rosty C, et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol 2003; 162: 1151-1162.
6. Iacobuzio-Donahue CA, Maitra A, Shen Ong GL, van Heek T, Ashfaq R, Meyer R, et al. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol 2002; 160: 1239-1249.
7. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-1806.
8. Tada, M, Omata M, Kawai S, Saisho H, Ohto M, Saiki RK, et al. Detection of RAS gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 1993; 53: 2472-2474.
9. Calhoun ES, Jones JB, Ashfaq R, Adsay V, Baker SJ, Valentine V, et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol 2003; 163: 1255-1260.
10. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
11. Feig LA. Ral-GTPases: approaching their 15 minutes of fame. Trends Cell Biol 2003; 13: 419-425.
12. Toubaji A, Achtar M, Provenzano M, Herrin VE, Behrens R, Hamilton M, et al. Pilot study of mutant RAS peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol Immunother 2008; 57: 1413-1420.
13. Rejiba S, Wack S, Aprahamian M, Hajri A. K-RAS oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment. Cancer Sci 2007; 98: 1128-1136.
14. Jimeno A, Rubio-Viqueira B, Amador ML, Grunwald V, Maitra A, Iacobuzio-Donahue C, et al. Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer. Mol Cancer Ther 2007; 6: 1079-1088.
15. Takayama Y, Kokuryo T, Yokoyama Y, Nagino M, Nimura Y, Senga T, et al. MeK inhibitor enhances the inhibitory effect of imatinib on pancreatic cancer cell growth. Cancer Lett 2008; 264: 241-249.
16. Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. Genes Dev 2001; 15: 3059-3087.
17. Lau J, Kawahira H, Hebrok M. Hedgehog signaling in pancreas development and disease. Cell Mol Life Sci 2006; 63: 642-652
18. Pasca di Magliano M, Sekine S, Ermilov A, Ferris J, Dlugosz AA, Hebrok M. Hedgehog/RAS interactions regulate early stages of pancreatic cancer. Genes Dev 2006; 20: 3161-3173.
19. Mongeau ME, Klimstra DS, Morris JP, Morris JP, Lee YC, Kawaguchi Y, et al. Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proc Natl Acad Sci U S A 2007; 104: 5103-5108.
20. Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R, Mullendore M, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 2007; 67: 2187-2196.
21. Ji Z, Mei FC, Xie J, Cheng X. Oncogenic K-RAS activates hedgehog signaling pathway in pancreatic cancer cells. J Biol Chem 2007; 282: 14048-14055.
22. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003; 425: 851-856.
23. Berman DM, Karhadkar SS, Maitra A, Montes De Oca R, Gerstenblith MR, Briggs K, et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 2003; 425: 846-851.
24. Xu FG, Ma QY, Wang Z. Blockade of hedgehog signaling pathway as a therapeutic strategy for pancreatic cancer. Cancer Lett 2009; 283: 119-124.
25. Shafaee Z, Schmidt H, Du W, Posner M. Cyclopamine increases the cytotoxic effects of paclitaxel and radiation but not cisplatin and gemcitabine in Hedgehog expressing pancreatic cancer cells. Cancer Chemother Pharmacol 2006; 58: 765-770.
26. Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R, Mullendore M, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 2007; 67: 2187-2196.
27. Hu WG, Liu T, Xiong JX. Blockade of sonic hedgehog signal pathway enhances antiproliferative effect of eGFr inhibitor in pancreatic cancer cells. Acta Pharmacol Sin 2007; 28: 1224-1230.
28. Mueller MT, Hermann PC, Witthauer J, Rubio-Viqueira B, Leicht SF, Huber S, et al. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 2009; 137: 1102-1113.
29. Simeone DM, Pham T, Logsdon CD. Disruption of TGFbeta signaling pathways in human pancreatic cancer cells. Ann Surg 2000; 232: 73-80.
30. Cook T, Urrutia R. TIEG proteins join the SMADs as TGF-beta-regulated transcription factors that control pancreatic cell growth. Am J Physiol Gastrointest Liver Physiol 2000; 278: G513-G521.
31. Sjolund J, Manetopoulos C, Stockhausen MT, Axelson H. The Notch pathway in cancer: differentiation gone awry. Eur J Cancer 2005; 41: 2620-2629.
32. Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 1998; 58: 5329-5332.
33. Levy L, Hill CS. SMAD4 dependency defines two classes of transforming growth factor? (TGF-?) target genes and distinguishes TGF-?-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol Cell Biol 2005; 25: 8108-8125.
34. Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, et al. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 2008; 7: 829-840.
35. Medicherla S, Li L, Ma JY, Kapoun AM, Gaspar NJ, Liu YW, et al. Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment. Anticancer Res 2007; 27: 4149-4157.
36. Cascinu S, Berardi R, Labianca R, Siena S, Falcone A, Aitini E, et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol 2008; 9: 39-44.
37. Zeng G, Germinaro M, Micsenyi A, Monga NK, Bell A, Sood A, et al. Aberrant wnt/beta-catenin signaling in pancreatic adenocarcinoma. Neoplasia 2006; 8: 279-289.
38. Pasca di Magliano M, Biankin AV, Heiser PW, Cano DA, Gutierrez PJ, Deramaudt T, et al. Common activation of canonical wnt signaling in pancreatic adenocarcinoma. PLoS ONE 2007; 2: e1155.
39. Nawroth R, van Zante A, Cervantes S, McManus M, Hebrok M, Rosen SD. Extracellular sulfatases, elements of the wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells. PLoS ONE 2007; 2: e392.
40. Romero D, Iglesias M, Vary CP, Quintanilla M. Functional blockade of SMAD4 leads to a decrease in beta-catenin levels and signaling activity in human pancreatic carcinoma cells. Carcinogenesis 2008; 29: 1070-1076.
41. Wang Z, Zhang Y, Li Y, Banerjee S, Liao J, Sarkar FH. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther 2006; 5: 483-493.
42. Wang Z, Zhang Y, Banerjee S, Li Y, Sarkar FH. Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 2006; 106: 2503-2513.
43. Dang T, Vo K, Washington K, Berlin J. The role of Notch3 signaling pathway in pancreatic cancer. J Clin Oncol 2007; 25: 21049.
44. Doucas H, Mann CD, Sutton CD, Garcea G, Neal CP, Berry DP, et al. Expression of nuclear Notch3 in pancreatic adenocarcinomas is associated with adverse clinical features, and correlateswith the expression of sTAT3 and phosphorylated Akt. J Surg Oncol 2008; 97: 63-68.
45. Miele L, Golde T, Osborne B. Notch signaling in cancer. Curr Mol Med 2006; 6: 905-918.
46. Wang Z, Zhang Y, Li Y, Banerjee S, Liao J, Sarkar FH. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther 2006; 5: 483-493.
47. Miyamoto Y, Maitra A, Ghosh B, Zechner U, Argani P, Iacobuzio-Donahue CA, et al. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 2003; 3: 565-576.
48. Welsch T, Kleeff J, Friess H. Molecular pathogenesis of pancreatic cancer: advances and challenges. Curr Mol Med 2007; 7: 504-521.
49. Magistrelli P, Coppola R, Tonini G, Vincenzi B, Santini D, Borzomati D, et al. Apoptotic index or a combination of Bax/Bcl-2 expression correlate with survival after resection of pancreatic adenocarcinoma. J Cell Biochem 2006; 97: 98-108.
50. Bu XM, Zhao CH, Dai XW. Aberrant expression of Wnt antagonist SFRP1 in pancreatic cancer. Chin Med J 2008; 121: 952-955.
51. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282: 1318-1321.
52. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-241.
53. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nuñez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997; 278: 687-689.
54. Jones RG, Parsons M, Bonnard M, Chan VS, Yeh WC, Woodgett JR, et al. Protein kinase B regulates T lymphocyte survival,nuclear factor kappaB activation, and Bcl-X(L) levels in vivo. J Exp Med 2000; 191: 1721-1734.
55. Schlieman MG, Fahy BN, Ramsamooj R, Beckett L, Bold RJ. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer 2003; 89: 2110-2115.
56. Fas SC, Fritzsching B, Suri-Payer E, Krammer PH. Death receptor signaling and its function in the immune system. Curr Dir Autoimmun 2006; 9: 1-17.
57. Vaux DL, Silke J. IAPs, RINGs and ubiquitylation. Nat Rev Mol Cell Biol 2005; 6: 287-297.
58. Esposito I, Kleeff J, Abiatari I, Shi X, Giese N, Bergmann F, et al. Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer. J Clin Pathol 2007; 60: 885-895.
59. Mori T, Doi R, Kida A, Nagai K, Kami K, Ito D, et al. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells. J Surg Res 2007; 142: 281-286.
60. Giagkousiklidis S, Vellanki SH, Debatin KM, Fulda S. Sensitization of pancreatic carcinoma cells for gamma-irradiation-induced apoptosis by XIAP inhibition. Oncogene 2007; 26: 7006-7016.
61. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA. The Pi 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-?B and c-Myc in pancreatic cancer cells. Oncogene 2004; 23: 8571-8580.
62. Abe N, Watanabe T, Masaki T, Mori T, Sugiyama M, Uchimura H, et al. Pancreatic duct cell carcinomas express high levels of high mobility group I(Y) proteins. Cancer Res 2000; 60: 3117-3122.
63. Liau SS, Whang E. HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma. Clin Cancer Res 2008; 14: 1470-1477.
64. Liau SS, Ashley SW, Whang EE. Lentivirus-mediated rNA interference of HMGA1 promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma. J Gastrointest Surg 2006; 10: 1254-1262.
65. Trapasso F, Sarti M, Cesari R, Yendamuri S, Dumon KR, Aqeilan RI, et al. Therapy of human pancreatic carcinoma based on suppression of HMGA1 protein synthesis in preclinical models. Cancer Gene Ther 2004; 11: 633-641.
66. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994; 8: 27-32.
67. Sellers WR, Rodgers JW, Kaelin WG Jr. A potent transrepression domain in the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites. Proc Natl Acad Sci U S A 1995; 92: 11544-11548.
68. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108-1113.
69. Lin J, Gan CM, Zhang X, Jones S, Sjöblom T, Wood LD, et al. A multidimensional analysis of genes mutated in breast and colorectal cancers. Genome Res 2007; 17: 1304-1318.
70. Parmigiani G, Boca S, Lin J, Kinzler KW, Velculescu V, Vogelstein B. Design and analysis issues in genome-wide somatic mutation studies of cancer. Genomics 2009; 93: 17-21.